Table S2. Assessment of study quality (revised Cochrane risk-of-bias tool for randomized trials, RoB 2)

1.	Risk of bias arising from the randomization process	1) Was the allocation sequence random? a) Y b) PY c) PN d) N e) NI 2) Was the allocation sequence concealed until participants were enrolled and assigned to the specified medication therapy? a) Y b) PY c) PN d) N e) NI 3) Did baseline differences between medication groups suggest a problem with the randomization process? a) Y b) PY c) PN d) N e) NI
2.	Risk of bias due to deviations from the intended interventions (effect of assignment to intervention)	1) Were participants aware of their assigned medication therapy during the trial? a) Y b) PY c) PN d) N e) NI 2) Were carers and people delivering the medication therapies aware of participants' assigned medication therapy during the trial? a) Y b) PY c) PN d) N e) NI 3) If Y/PY/NI to 1) or 2) Were there deviations from the intended medication therapy that arose because of the trial context? a) Y b) PY c) PN d) N e) NI 4) If Y/PY to 3) Were these deviations likely to have affected the frailty outcome? a) Y b) PY c) PN d) N e) NI 5) If Y/PY/NI to 4) Were these deviations from intended medication therapy balanced between groups? a) Y b) PY c) PN d) N e) NI 6) Was an appropriate analysis used to estimate the effect of assignment to medication therapy? a) Y b) PY c) PN d) N e) NI 7) If N/PN/NI to 6) Was there potential for a substantial impact (on the result) of the failure to analyze participants in the group to which they were randomized? a) Y b) PY c) PN d) N e) NI
	(Effect of adhering to intervention)	1) Were participants aware of their assigned medication therapy during the trial? a) Y b) PY c) PN d) N e) NI 2) Were carers and people delivering the medication therapies aware of participants' assigned medication therapy during the trial? a) Y b) PY c) PN d) N e) NI 3) If Y/PY/NI to 1) or 2) Were important non-protocol medication therapy balanced across intervention groups? a) Y b) PY c) PN d) N e) NI 4) (If applicable) Were there failures in implementing medication therapy that could have affected the frailty outcome? a) Y b) PY c) PN d) N e) NI 5) (If applicable) Was there non-adherence to the assigned medication therapy that could have affected participants' frailty outcomes? a) Y b) PY c) PN d) N e) NI 6) If N/PN/NI to 3), or Y/PY/NI to 4) or 5) Was an appropriate analysis used to estimate the effect of adhering to the medication therapy? a) Y b) PY c) PN d) N e) NI
3.	Risk of bias due to missing outcome data	1) Were data for frailty outcomes available for all, or nearly all, participants randomized? a) Y b) PY c) PN d) N e) NI 2) If N/PN/NI to 1) Is there evidence that the result was not biased by missing frailty outcome data? a) Y b) PY c) PN d) N e) NI

		3) If N/PN to 2) Could missingness in the outcome depend on its true value? a) Y b) PY c) PN d) N e) NI 4) If Y/PY/NI to 3) Is it likely that missingness in the frailty outcome depended on its true value? a) Y b) PY c) PN d) N e) NI
4.	Risk of bias in measurement of the outcome	1) Was the method of measuring frailty outcome inappropriate? a) Y b) PY c) PN d) N e) NI 2) Could measurement or ascertainment of the frailty outcome have differed between medication therapy groups? a) Y b) PY c) PN d) N e) NI 3) If N/PN/NI to 1) and 2) Were outcome assessors aware of the medication therapy received by study participants? a) Y b) PY c) PN d) N e) NI 4) If Y/PY/NI to 3) Could assessment of the frailty outcome have been influenced by knowledge of medication therapy received? a) Y b) PY c) PN d) N e) NI 5) If Y/PY/NI to 4) Is it likely that assessment of the frailty outcome was influenced by knowledge of medication therapy received? a) Y b) PY c) PN d) N e) NI
5.	Risk of bias in selection of the reported result	1) Were the data that produced this result analyzed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis? a) Y b) PY c) PN d) N e) NI 2) Is the numerical result being assessed likely to have been selected, on the basis of the results, from either: 2.1) Multiple eligible outcome measurements within the outcome domain? a) Yb) PY c) PN d) N e) NI 2.2) Multiple eligible analyses of the data? a) Y b) PY c) PN d) N e) NI

Y, yes; PY, partial yes; PN, partial no; N, no; NI, no information.